Top Feature

Jul 09, 2014
By Pharmaceutical Executive Editors
The pharma spin market is moving up a gear as companies see the imperative to tap into brand value. Allen Gove explains how understanding what the company is about is critical to bolstering the value of the product.
Jun 04, 2014
By Pharmaceutical Executive Editors
Elderly patients are underrepresented in clinical trials, but there are few obstacles to including this patient group in trials that cannot be overcome, writes Sydney Rubin.
May 15, 2014
From BioPharm International
By Pharmaceutical Executive Editors
India must still be included in the list of promising potential markets for global pharmaceutical manufacturers, write Jill E. Sackman and Michael Kuchenreuther.
Feb 21, 2014
By Pharmaceutical Executive Editors
With 2014 shaping up to be a pivotal year for the American pharma industry, Tom Norton wonders how much longer American dominance in R&D spending can continue.
Feb 18, 2014
Pharmaceutical Executive
A global life-cycle management strategy should be baked into a drug's initial price at launch, write Alice Swearingen and Patrick Homer.
Nov 25, 2013
Pharmaceutical Executive
Pharm Exec convenes a diverse panel of experts to identify the key markers of common ground: its time, people, and money against that greatest intangible—hope.
Nov 05, 2013
The GSK bribery investigations in China has given recruiters pause for thought. Gregory Lovas offers some do's and don'ts for keeping your emerging market recruitment drive on track.
Oct 14, 2013
An increasing number of small biotech companies are being hatched to focus on a single disease or condition. PharmExec talks to the CEO of one such company, Eugene Williams of Dart Therapeutics.
Oct 10, 2013
As insurers, payers, and drug plan operators eye increased generic drug use as key to cutting healthcare costs, pharma companies are ramping up efforts to delay marketing of copycat products.
Oct 03, 2013
From Pharmaceutical Technology
Industry experts talk to Pharmaceutical Technology's Adeline Siew about the requirements and challenges involved in getting a biosimilar product to market.
native1_300x100
lorem ipsum